<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731727</url>
  </required_header>
  <id_info>
    <org_study_id>0000</org_study_id>
    <nct_id>NCT04731727</nct_id>
  </id_info>
  <brief_title>Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)</brief_title>
  <acronym>CXL</acronym>
  <official_title>Safety and Effectiveness of the CCL Vario System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kent Wellish MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wellish Vision Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2&#xD;
      (Riboflavin) and the application on UV Light.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corneal thinning conditions, i.e. keratoconus or ectasia, weaken the cornea which then causes&#xD;
      the front of the eye to bulge out. This results in distorted vision and could eventually&#xD;
      result in the need for a cornea transplant. This study proposes to conclude that saturating&#xD;
      the cornea with vitamin B2 (Riboflavin) and then applying 365nm wavelength of Ultra Violet&#xD;
      Light will result in the various layers of corneal tissue linking together. This cross&#xD;
      linking results in a stronger cornea which is designed to halt the progression of keratoconus&#xD;
      or ectasia. This treatment is already being successfully used in Europe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best Corrected Visual Acuity</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Use a standard eye chart to determine changes in the subject's best Visual Acuity (with glasses or contact) performed by research staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Uncorrected Visual Acuity</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Use a standard eye chart to determine changes in the subject's best Visual Acuity (without glasses or contact) performed by clinic technician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Surgeon notes any occurrence of adverse events related to the treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Keratoconus, Unstable</condition>
  <arm_group>
    <arm_group_label>Cross linking treatment for corneal thinning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Corneal cross linking achieved by combination of Riboflavin and ultraviolet light</description>
    <arm_group_label>Cross linking treatment for corneal thinning</arm_group_label>
    <other_name>Ultra violet light</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of central or inferior corneal steepening&#xD;
&#xD;
          -  Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid&#xD;
             marginal degeneration&#xD;
&#xD;
          -  Presence of one or more findings associated with keratoconus or pellucid marginal&#xD;
             degeneration, such as:&#xD;
&#xD;
          -  Fleischer ring&#xD;
&#xD;
          -  Vogt's striae&#xD;
&#xD;
          -  Decentered corneal apex&#xD;
&#xD;
          -  Munson's sign&#xD;
&#xD;
          -  Rizutti's sign&#xD;
&#xD;
          -  Apical corneal scarring consistent with Bowman's breaks&#xD;
&#xD;
          -  Scissoring of the retinoscopic reflex&#xD;
&#xD;
          -  Crab-claw appearance on topography&#xD;
&#xD;
          -  Steepest keratometry (Kmax) value &gt; or = 47.20 D&#xD;
&#xD;
          -  I-S keratometry difference &gt; 1.5 D on the Orbscan map&#xD;
&#xD;
          -  Posterior corneal elevation &gt; 16 microns&#xD;
&#xD;
          -  Thinnest corneal point &lt; 485 microns&#xD;
&#xD;
          -  Post LASIK/PRK stromal ablation depth &lt; 300 microns or expected keratometry &gt; 47.2 D,&#xD;
             or post-PRK/SMILE in keratoconus suspect eyes&#xD;
&#xD;
          -  Bacterial or fungal corneal keratitis persistent and not responding despite &gt; 2 weeks&#xD;
             of standard antimicrobial therapy or with rapid progression of corneal thinning, with&#xD;
             loss of &gt; 25% corneal thickness&#xD;
&#xD;
          -  Contact Lens Wearers Only:&#xD;
&#xD;
          -  Removal of contact lenses for the required period of time prior to the screening&#xD;
             refraction:&#xD;
&#xD;
        Contact Lens Type Minimum Discontinuation Time Soft 1 Week Soft Extended Wear 2 Weeks Soft&#xD;
        Toric 3 Weeks Rigid Gas Permeable 2 Weeks per decade of wear&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Willingness and ability to comply with schedule for follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eyes classified as either normal or atypical normal on the severity grading scheme&#xD;
&#xD;
          -  Corneal pachymetry at the screening exam that is &lt; 400 microns at the thinnest point&#xD;
             in the eye(s) to be treated when the transepithelial (isotonic) riboflavin solution&#xD;
             alone will be used or &lt; 300 microns when the hypotonic riboflavin will be used.&#xD;
&#xD;
          -  Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example:&#xD;
&#xD;
               1. History of or active corneal disease (e.g., herpes simplex, herpes zoster&#xD;
                  keratitis, recurrent erosion syndrome, acanthamoeba, etc.)&#xD;
&#xD;
               2. Clinically significant corneal scarring in the CXL treatment zone that is not&#xD;
                  related to keratoconus or, in the investigator's opinion, will interfere with the&#xD;
                  cross linking procedure&#xD;
&#xD;
          -  Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
&#xD;
          -  A known sensitivity to study medications&#xD;
&#xD;
          -  Patients with nystagmus or any other condition that would prevent a steady gaze during&#xD;
             the CXL treatment or other diagnostic tests&#xD;
&#xD;
          -  Patients with a current condition that, in the physician's opinion, would interfere&#xD;
             with or prolong epithelial healing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent L Wellish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellish Vision Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tony F Sterrett</last_name>
    <phone>702-932-4265</phone>
    <email>tsterrett@wellish.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kent L Wellish, MD</last_name>
    <phone>702-339-2020</phone>
    <email>klwellish@gmail.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wellish Vision Institute</investigator_affiliation>
    <investigator_full_name>Kent Wellish MD</investigator_full_name>
    <investigator_title>President and Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Unidentifiable patient data and pre- and post-op results will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

